To conclude this section on anti-HER2 targeted therapies in NSCLC, a meta-analysis pooled data from 32 clinical trials, which included 958 patients treated with various anti-HER2 therapies ranging from TKIs to ADCs [141]. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.